Cargando…

Effects of primary granulocyte-colony stimulating factor prophylaxis on the incidence of febrile neutropenia in patients with germ cell tumors

Testicular germ cell tumors (GCTs) are the most common solid malignancy in males aged 15–35 years. Febrile neutropenia (FN) is a serious complication of chemotherapy that frequently occurs in patients with GCTs. The present retrospective study aimed to evaluate the effect of primary granulocyte-colo...

Descripción completa

Detalles Bibliográficos
Autores principales: Hapakova, Nikola, Chovanec, Michal, Rejlekova, Katarina, Kalavska, Katarina, Obertova, Jana, Palacka, Patrik, De Angelis, Valentina, Svetlovska, Daniela, Sycova-Mila, Zuzana, Mardiak, Jozef, Mego, Michal
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9353223/
https://www.ncbi.nlm.nih.gov/pubmed/35949605
http://dx.doi.org/10.3892/ol.2022.13428
_version_ 1784762828441255936
author Hapakova, Nikola
Chovanec, Michal
Rejlekova, Katarina
Kalavska, Katarina
Obertova, Jana
Palacka, Patrik
De Angelis, Valentina
Svetlovska, Daniela
Sycova-Mila, Zuzana
Mardiak, Jozef
Mego, Michal
author_facet Hapakova, Nikola
Chovanec, Michal
Rejlekova, Katarina
Kalavska, Katarina
Obertova, Jana
Palacka, Patrik
De Angelis, Valentina
Svetlovska, Daniela
Sycova-Mila, Zuzana
Mardiak, Jozef
Mego, Michal
author_sort Hapakova, Nikola
collection PubMed
description Testicular germ cell tumors (GCTs) are the most common solid malignancy in males aged 15–35 years. Febrile neutropenia (FN) is a serious complication of chemotherapy that frequently occurs in patients with GCTs. The present retrospective study aimed to evaluate the effect of primary granulocyte-colony stimulating factor (G-CSF) prophylaxis on the incidence of FN in patients with GCTs. The present study included a review of the medical records of patients diagnosed with GCTs treated with first-line/adjuvant chemotherapy between January 2000 and December 2017 at the National Cancer Institute (Bratislava, Slovakia). In January 2006, a decision was made to administer G-CSF prophylaxis (filgrastim or pegfilgrastim) to patients after every cycle of chemotherapy. The present study included 385 patients, and out of these, 264 patients received primary G-CSF prophylaxis, while 121 patients did not. A total of 71 patients (18.4%) suffered from FN events. In the subgroup that did not receive primary prophylaxis, 42 patients exhibited FN, while only 29 patients with primary prophylaxis suffered from FN (34.7 vs. 11.0%; P=0.00000003). According to the subgroup analysis, FN incidence was decreased in all groups that received primary prophylaxis, except for patients with stage I GCT receiving adjuvant chemotherapy, without affecting overall survival. Primary G-CSF prophylaxis was associated with markedly reduced FN incidence in patients treated with first-line chemotherapy for metastatic disease. Therefore, the results of the present study suggested that primary G-CSF prophylaxis should be considered in patients with GCT receiving first-line chemotherapy.
format Online
Article
Text
id pubmed-9353223
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher D.A. Spandidos
record_format MEDLINE/PubMed
spelling pubmed-93532232022-08-09 Effects of primary granulocyte-colony stimulating factor prophylaxis on the incidence of febrile neutropenia in patients with germ cell tumors Hapakova, Nikola Chovanec, Michal Rejlekova, Katarina Kalavska, Katarina Obertova, Jana Palacka, Patrik De Angelis, Valentina Svetlovska, Daniela Sycova-Mila, Zuzana Mardiak, Jozef Mego, Michal Oncol Lett Articles Testicular germ cell tumors (GCTs) are the most common solid malignancy in males aged 15–35 years. Febrile neutropenia (FN) is a serious complication of chemotherapy that frequently occurs in patients with GCTs. The present retrospective study aimed to evaluate the effect of primary granulocyte-colony stimulating factor (G-CSF) prophylaxis on the incidence of FN in patients with GCTs. The present study included a review of the medical records of patients diagnosed with GCTs treated with first-line/adjuvant chemotherapy between January 2000 and December 2017 at the National Cancer Institute (Bratislava, Slovakia). In January 2006, a decision was made to administer G-CSF prophylaxis (filgrastim or pegfilgrastim) to patients after every cycle of chemotherapy. The present study included 385 patients, and out of these, 264 patients received primary G-CSF prophylaxis, while 121 patients did not. A total of 71 patients (18.4%) suffered from FN events. In the subgroup that did not receive primary prophylaxis, 42 patients exhibited FN, while only 29 patients with primary prophylaxis suffered from FN (34.7 vs. 11.0%; P=0.00000003). According to the subgroup analysis, FN incidence was decreased in all groups that received primary prophylaxis, except for patients with stage I GCT receiving adjuvant chemotherapy, without affecting overall survival. Primary G-CSF prophylaxis was associated with markedly reduced FN incidence in patients treated with first-line chemotherapy for metastatic disease. Therefore, the results of the present study suggested that primary G-CSF prophylaxis should be considered in patients with GCT receiving first-line chemotherapy. D.A. Spandidos 2022-07-13 /pmc/articles/PMC9353223/ /pubmed/35949605 http://dx.doi.org/10.3892/ol.2022.13428 Text en Copyright: © Hapakova et al. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License (https://creativecommons.org/licenses/by-nc-nd/4.0/) , which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
spellingShingle Articles
Hapakova, Nikola
Chovanec, Michal
Rejlekova, Katarina
Kalavska, Katarina
Obertova, Jana
Palacka, Patrik
De Angelis, Valentina
Svetlovska, Daniela
Sycova-Mila, Zuzana
Mardiak, Jozef
Mego, Michal
Effects of primary granulocyte-colony stimulating factor prophylaxis on the incidence of febrile neutropenia in patients with germ cell tumors
title Effects of primary granulocyte-colony stimulating factor prophylaxis on the incidence of febrile neutropenia in patients with germ cell tumors
title_full Effects of primary granulocyte-colony stimulating factor prophylaxis on the incidence of febrile neutropenia in patients with germ cell tumors
title_fullStr Effects of primary granulocyte-colony stimulating factor prophylaxis on the incidence of febrile neutropenia in patients with germ cell tumors
title_full_unstemmed Effects of primary granulocyte-colony stimulating factor prophylaxis on the incidence of febrile neutropenia in patients with germ cell tumors
title_short Effects of primary granulocyte-colony stimulating factor prophylaxis on the incidence of febrile neutropenia in patients with germ cell tumors
title_sort effects of primary granulocyte-colony stimulating factor prophylaxis on the incidence of febrile neutropenia in patients with germ cell tumors
topic Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9353223/
https://www.ncbi.nlm.nih.gov/pubmed/35949605
http://dx.doi.org/10.3892/ol.2022.13428
work_keys_str_mv AT hapakovanikola effectsofprimarygranulocytecolonystimulatingfactorprophylaxisontheincidenceoffebrileneutropeniainpatientswithgermcelltumors
AT chovanecmichal effectsofprimarygranulocytecolonystimulatingfactorprophylaxisontheincidenceoffebrileneutropeniainpatientswithgermcelltumors
AT rejlekovakatarina effectsofprimarygranulocytecolonystimulatingfactorprophylaxisontheincidenceoffebrileneutropeniainpatientswithgermcelltumors
AT kalavskakatarina effectsofprimarygranulocytecolonystimulatingfactorprophylaxisontheincidenceoffebrileneutropeniainpatientswithgermcelltumors
AT obertovajana effectsofprimarygranulocytecolonystimulatingfactorprophylaxisontheincidenceoffebrileneutropeniainpatientswithgermcelltumors
AT palackapatrik effectsofprimarygranulocytecolonystimulatingfactorprophylaxisontheincidenceoffebrileneutropeniainpatientswithgermcelltumors
AT deangelisvalentina effectsofprimarygranulocytecolonystimulatingfactorprophylaxisontheincidenceoffebrileneutropeniainpatientswithgermcelltumors
AT svetlovskadaniela effectsofprimarygranulocytecolonystimulatingfactorprophylaxisontheincidenceoffebrileneutropeniainpatientswithgermcelltumors
AT sycovamilazuzana effectsofprimarygranulocytecolonystimulatingfactorprophylaxisontheincidenceoffebrileneutropeniainpatientswithgermcelltumors
AT mardiakjozef effectsofprimarygranulocytecolonystimulatingfactorprophylaxisontheincidenceoffebrileneutropeniainpatientswithgermcelltumors
AT megomichal effectsofprimarygranulocytecolonystimulatingfactorprophylaxisontheincidenceoffebrileneutropeniainpatientswithgermcelltumors